Publication Name	World Journal of Clinical Oncology
Manuscript ID	108768
Country	China

Category	Medicine, Research & Experimental
Manuscript Type	Editorial
Article Title	Potential risks of histone deacetylase inhibitors in cancer therapeutics and feasible combination therapeutic strategies
Manuscript Source	Invited Manuscript
All Author List	Shuai Xiao, Xiao-Zhen Xu, Meng Liao, Dan-Dan Song, Jing-Feng Tang and Ce-Fan Zhou
Funding Agency and Grant Number	Funding Agency Grant Number National Natural Science Foundation of China 32270768 National Natural Science Foundation of China 82273970 National Natural Science Foundation of China 32070726 National Natural Science Foundation of China 82370715 Hubei Natural Science Foundation of China 2024AFB218 National Key R&D Program of China 2023YFC2507904 Doctoral Start-up Foundation of Hubei University of Technology XJ2022003901
Corresponding Author	Ce-Fan Zhou, Professor, School of Life and Health Sciences, Institute of Biomedical Research, National "111" Center for Cellular Regulation and Molecular Pharmaceutics, Key Laboratory of Fermentation Engineering (Ministry of Education), Hubei University of Technology, No. 28 Nanli Road, Wuhan 430068, Hubei Province, China. cefan@hbut.edu.cn
Key Words	Histone deacetylase inhibitors; Trichostatin A; Combination therapeutics; Selective inhibitors; Multidrug resistance
Core Tip	Histone deacetylase inhibitors (HDACis) have been extensively researched for their potential anticancer effects. However, in addition to their role in inhibiting tumor growth, it has also surprisingly facilitated the metastasis of esophageal squamous cell carcinoma. Clinical studies indicate that the effectiveness of HDACis in treating solid tumors often falls short of expectations, and these inhibitors may inherently carry certain risks. In this article, we examine the potential dangers associated with the clinical use of HDACis, including severe adverse effects, off-target toxicities, multidrug resistance, and limited efficiency in solid tumors. Furthermore, future research should focus on combination therapies, the development of selective or dual-target inhibitors to mitigate the adverse effects of HDACis treatments.
Citation	Xiao S, Xu XZ, Liao M, Song DD, Tang JF, Zhou CF. Potential risks of histone deacetylase inhibitors in cancer therapeutics and feasible combination therapeutic strategies. World J Clin Oncol 2025; In press

Received	2025-04-23 04:11
Peer-Review Started	2025-04-23 04:12
To Make the First Decision
Return for Revision	2025-05-14 06:04
Revised	2025-05-21 06:33
Second Decision	2025-07-10 02:46
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2025-07-10 06:13
Articles in Press	2025-07-10 06:13
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript

ISSN	2218-4333 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com